Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells

European Journal of Haematology

Volumn 56, Issue 1-2, 1996, Pages 12-22

  Hegewisch Becker, S ^a   Faltz, C ^a   Hossfeld, D K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute leukaemia; Daunorubicin accumulation; Growth condition; Multidrug resistance; P glycoprotein

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MERCAPTOPURINE; PREDNISOLONE; VERAPAMIL; VINCRISTINE;

ACUTE LEUKEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0029864842     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00287.x     Document Type: Article

References (26)

1. MARUYAMA Y, MUROHASHI I, NARA N, AOKI N. Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia. Br J Haematol 1989: 72: 357-362.
2. KATO S, IDEGUCHI H, MUTA K, NISHIMURA J, NAWATA H. Absence of correlation between cytotoxicity and drug transport by P-glycoprotein in clinical leukemic cells. Eur J Haematol 1991: 47: 146-151.
3. CAMPOS L, GUYOTAT D, JAFFAR C, SOLARY E, ARCHIMBAUD E, TREILLE D. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. Eur J Haematol 1992: 48: 254-258.
4. ROSS DD, WOOTEN PJ, SRIDHARA R, ORDONEZ JV, LEE EJ, SCHIFFER CA. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993: 82: 1288-1299.
5. HEGEWISCH-BECKER S, FLIEGNER M, TSURUO T, ZELLER W, HOSSFELD DK. Multidrug resistance (mdrl) in adult acute leukemia at diagnosis: correlation with response to induction chemotherapy. Onkologie 1993: 16: 264-269.
6. HEGEWISCH-BECKER S, FLIEGNER M, HOSSFELD DK, ZANDER A. Clinical relevance of P-glycoprotein expression and drug uptake. Proc Am Assoc Cancer Res 1991: 32: 434.
7. BROXTERMAN HJ, PINEDO HM, KUIPER CM, KAPTEIN LCM, SCHUURHUIS GJ, LANKELMA J. Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J 1988: 2: 2278-2282.
8. NOONAN KE, BECK C, HOLZMAYER TA, et al. Quantitative analysis of mdr1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci 1990: 87: 7160-7164.
9. VISSER JWM, VAN DEN ENGH GJ, VAN BEKKUM DW. Light scattering properties of murine hemopoietic cells. Blood Cells 1980: 6: 391-407.
10. KOKENBERG E, SONNEVELD P, DELWEL R, SIZOO W, HAGENBEEK A, LÖWENBERG B. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 1988: 2: 511-517.
11. LUDESCHER C, THALER J, DRACH D, et al. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 1992: 82: 161-168.
12. ZAMAN GJR, FLENS MJ, VAN LEUSDEN MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 1994: 91: 8822-8826.
13. BROXTERMAN HJ. How to probe clinical cancer specimens for MDR. Anti-Cancer Drugs 1994: 5: 67.
14. HERWEIJER H, SONNEVELD P, BAAS F, NOOTER K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990: 82: 1133-1140.
15. NOOTER K, SONNEVELD P, OOSTRUM R, HERWEIJER H, HAGENBEEK N, VALERIO D. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin A. Int J Cancer 1990: 45: 263-268.
16. MARIE J-P, FAUSSAT-SUBERVILLE A-M, ZHOU D, ZITTOUN R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993: 7: 825-831.
17. TANIMURA H, KOHNO K, SATO S, et al. The human multidrug resistance 1 promoter has an element that responds to serum starvation. Biochem Biophys Res Commun 1992: 183: 917-924.
18. WILLINGHAM MC, CORNWELL MM, CARDARELLI CO, GOTTESMAN MM, PASTAN I. Single cell analysis of daunomycin uptake in multidrug resistant and sensitive KB cells: effects of verapamil and other drugs. Cancer Res 1986: 46: 5941-5946.
19. SCHINKEL AH, SMIT JJM, VAN TELLINGEN O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity of drugs. Cell 1994: 77: 491-502.
20. SATO H, PREISLER R, DAY R, et al. Mdr 1 transcript levels as an indication of resistant disease in acute myelogenous leukemia. Br J Haematol 1990: 75: 340-345.
21. PIRKER R, WALLER J, GEISSLER K, BETTELHEIM P, LINKESCH W, LECHNER K. Mdr1 gen expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991: 83: 701-712.
22. CAMPOS L, GUYOTAT D, ARCHIMBAUT E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992: 79: 473-476.
23. GOASGUEN JE, DOSSOT J-M, FARDEL O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993: 81: 2394-2398.
24. BALL ED, LAWRENCE D, MALNAR M, et al. Correlation of CD34 and multidrug resistance P170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML). Blood 1990: 76: 252a.
25. WILLMAN CL, KOPECKY KJ, WEIK J, et al. Biologic parameters that predict response in de novo acute myeloid leukemia (AML): CD34 but not multidrug resistance (MDR) gene expression is associated with a decreased complete remission (CR) rate and CD34 + patients more frequently achieve CR with high dose cytosine arabinoside. Proc Am Soc Clin Oncol 1992: 11: 262.
26. LIST AF, SPIER C, GREER J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993: 9: 1652-1660.